Table 1.
N | squamous-cell carcinoma N = 1489 |
adeno- & adenosq. carcinoma N = 182 |
Test Statistic | |
---|---|---|---|---|
Age (years) | 1671 | 46.5 (38.8–55.9) | 46.0 (54.6–39.4) | P = 0.561 |
Race/Ethnicity | 1671 | P = 0.0772 | ||
White | 59.9% (892) | 64.8% (118) | ||
Black | 24.3% (362) | 15.9% (29) | ||
Hispanic, other | 12.2% (182) | 15.4% (28) | ||
Asian | 3.6% (53) | 3.8% (7) | ||
Performance status | 1671 | P = 0.4592 | ||
normal, asymptomatic | 70.9% (1055) | 75.3% (137) | ||
symptomatic, ambulatory | 25.4% (378) | 21.4% (39) | ||
symptomatic, in bed | 3.8% (56) | 3.3% (6) | ||
Tumor size (cm) | 1659 | 6.0 (5.0–8.0) | 6.0 (5.0–7.0) | P < 0.0011 |
Tumor size (cm) | 1659 | P = 0.0052 | ||
< 5.0 | 15.8% (234) | 22.5% (41) | ||
5.0–6.0 | 18.8% (278) | 24.7% (45) | ||
6.0–7.5 | 38.9% (575) | 35.2% (64) | ||
≥ 7.5 | 26.4% (390) | 17.6% (32) | ||
FIGO stage | 1671 | P = 0.1022 | ||
IB2 | 20.0% (298) | 27.5% (50) | ||
IIB | 47.1% (702) | 47.3% (86) | ||
IIIA | 1.3% (20) | 1.6% (3) | ||
IIIB | 28.6% (426) | 21.4% (39) | ||
IVA | 2.9% (43) | 2.2% (4) | ||
Tumor grade (differentiation) | 1671 | P < 0.0012 | ||
well | 5.5% (82) | 14.3% (26) | ||
moderate | 65.3% (972) | 37.9% (69) | ||
poor | 26.9% (400) | 46.2% (84) | ||
not graded | 2.4% (35) | 1.6% (3) | ||
Hydronephrosis | 1671 | P = 0.62 | ||
none | 88.9% (1324) | 91.2% (166) | ||
unilateral | 8.8% (131) | 6.6% (12) | ||
bilateral | 2.3% (34) | 2.2% (4) | ||
Parametrial involvement | 1671 | P = 0.1082 | ||
none | 21.7% (323) | 28.6% (52) | ||
unilateral | 46.3% (689) | 42.9% (78) | ||
bilateral | 32.0% (477) | 28.6% (52) | ||
Pelvic nodes | 1671 | P = 0.0332 | ||
positive | 10.3% (154) | 15.9% (29) | ||
negative | 62.8% (935) | 63.2% (115) | ||
unknown | 26.9% (400) | 20.9% (38) |
b (a–c) represent the lower quartile a, the median b, and the upper quartile c for continuous variables.
N is the number of non–missing values.
Numbers after percents are frequencies.
Tests used:
Wilcoxon test;
Pearson test